ZIP Solutions –Bionaturis Group- has just been granted with a new patent titled “Protein Body-inducing Polypeptide Sequences” for EEUU, becoming the third patent of the same family, already obtained for Japan and Europe. This patent contributes to a better protection of the Zera Subunit Vaccines 2.0 and Zera DNA Vaccines outstanding applications.

After the granting by The United States Patent and Trademark Office (USPTO), this ZIP Solutions invention is protected in three relevant international markets. The patent family claims the use of second-generation self-assembly fusion sequences, Zera®2, to express and produce recombinant proteins in eukaryotic hosts forming protein bodies. Zera®2 aims to standardize the immune response raised by recombinant vaccines and DNA vaccines plus elimination of the cold-chain by formation of metastable nanostructures.

For further information about this patent, please, click here 

Zera Intein Protein Solutions (ZIP) is all-round bioprocessing, developing and offering highly effective tools for industrial applications of protein-based products such as peptides, recombinant antigens, enzymes, nanobodies, among others. Proprietaries Zera® and Splittera systems – the later subject of an exclusive and worldwide license to a leading multinational company- are optimal solutions to express and purify biological products at industrial scale.

Please, click here to read the Relevant Information (Only in Spanish)

About Bionaturis Group

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. Bionaturis lists on the Spanish stock exchange for SMEs (trading code BNT).